Heightened US antitrust fears rattle biopharma

A rash of recent large acquisitions had biopharma investors hoping that lean times for M&A might be coming to an end. But those lifted spirits were sent plummeting back to earth today by confirmation that the US Federal Trade Commission is challenging Amgen’s $28bn takeout of Horizon.